GnRHa

PreclinicalSmall molecule

SSecond Affiliated Hospital of Wenzhou Medical University

GnRHa is one of 52 small molecule programs targeting Short stature. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short StatureActive, not recruiting

TreatmentUnknown status

Fertility PreservationUnknown status

Intrauterine InseminationCompleted

Short StaturePreclinical

Active, not recruiting

TreatmentPreclinical

Unknown status

Fertility PreservationPreclinical

Unknown status

Intrauterine InseminationPreclinical

Completed

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Minipress

Pfizer

Preclinical

1 6

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 7

Intuniv

PPromius Pharma, LLC

Preclinical

1 8

Clomid

Ferring

Preclinical

1 9

Aurlumyn

BBTG International Inc.

Preclinical

1 10

Lotemax

PPharmos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ANot yet recruiting

Short Stature

NCT06768411

Q1 2028

PreclinicalRecruiting

Endometrial Neoplasms

NCT05316935

Clinical

Trials by Indication[1]

Short stature1 trial

The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children

Not yet recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT06768411·240 enrolled

Toxicity1 trial

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Completed·XXiangyun Zong·Phase 3·NCT02518191·345 enrolled

Laparoscopic1 trial

Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy

Unknown status·AAmsterdam UMC, location VUmc·Phase 4·NCT02288130·100 enrolled

Intrauterine Insemination1 trial

GnRH Agonist Versus hCG Trigger in Ovulation Induction With Intrauterine Insemination.

Completed·HHue University of Medicine and Pharmacy·N/A·NCT03825445·197 enrolled

Fertility Preservation1 trial

The Clinical Significance of Ovarian Function Detection and Protection in Fertility Preservation Surgery for Ovarian Malignancy

Unknown status·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT03882190·20 enrolled

2 more indications

Treatment1 trial

Comparison of the Therapeutic Effects of VR and VR + GnRHa in the Treatment of Cesarean Scar Diverticula

Unknown status·XXipeng Wang·N/A·NCT02932761·220 enrolled

Endometrial Neoplasms1 trial

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Non-obese Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment

Recruiting·XXiaojun Chen·Preclinical·NCT05316935·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for GnRHa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GnRHa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GnRHa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Wenzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSecond Affiliated Hospital of Wenzhou Medical University

GnRHa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Trials by Indication[1]

Short stature1 trial

Toxicity1 trial

Laparoscopic1 trial

Intrauterine Insemination1 trial

Fertility Preservation1 trial

Treatment1 trial

Endometrial Neoplasms1 trial

References

Drug Info

Quick Facts

Related News